Patients treated with a 0.38% submicron formulation of loteprednol etabonate gel after cataract surgery reported less pain and inflammation than those treated with a vehicle-only product.
The double-masked, vehicle-controlled randomized parallel group study included 514 patients who were randomly assigned to one of three treatment groups: 171 patients received loteprednol etabonate gel (Bausch + Lomb) three times a day, 171 patients received loteprednol etabonate gel two times a day, and 172 patients received a vehicle-only product that did not contain loteprednol etabonate.
The primary
Uncategorized